Last reviewed · How we verify
Adriamycin+Cyclophosphamide>Docetaxel
This sequential chemotherapy regimen uses anthracycline and alkylating agents followed by a taxane to damage cancer cell DNA and disrupt microtubule formation, inducing apoptosis in rapidly dividing cells.
This sequential chemotherapy regimen uses anthracycline and alkylating agents followed by a taxane to damage cancer cell DNA and disrupt microtubule formation, inducing apoptosis in rapidly dividing cells. Used for Breast cancer (neoadjuvant or adjuvant treatment), HER2-negative breast cancer.
At a glance
| Generic name | Adriamycin+Cyclophosphamide>Docetaxel |
|---|---|
| Also known as | Chemotherapy |
| Sponsor | Asan Medical Center |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Adriamycin (doxorubicin) and cyclophosphamide work synergistically as DNA-damaging agents in the initial phase, followed by docetaxel, a microtubule-stabilizing taxane that prevents cell division. This sequential approach (AC→T) is designed to maximize cytotoxic effect while managing cumulative toxicity, commonly used in breast cancer treatment to target both rapidly dividing tumor cells and micrometastatic disease.
Approved indications
- Breast cancer (neoadjuvant or adjuvant treatment)
- HER2-negative breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Alopecia
- Mucositis
- Peripheral neuropathy (docetaxel phase)
- Cardiotoxicity (doxorubicin-related)
- Fatigue
Key clinical trials
- Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (PHASE2)
- Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (PHASE2)
- Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer (NA)
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
- Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer (PHASE2)
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy (PHASE2)
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adriamycin+Cyclophosphamide>Docetaxel CI brief — competitive landscape report
- Adriamycin+Cyclophosphamide>Docetaxel updates RSS · CI watch RSS
- Asan Medical Center portfolio CI